课题基金 / 基金详情

LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM

LIPIN 1 IN THE REGULATION OF HEPATIC LIPID METABOLISM
LIPIN 1 对肝脏脂质代谢的调节
批准号:
8436991
负责人:
Brian N Finck
金额:
$33.06万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-01-01 至 2017-01-31

项目摘要

项目成果

Brian N Finck的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Overwhelming evidence links obesity with increased risk for several chronic diseases including non- alcoholic fatty liver disease (NAFLD). The condition, NAFLD, encompasses both simple hepatic steatosis and the more severe non-alcoholic steatohepatitis (NASH; hepatic inflammation and fibrosis associated with steatotic lesions). With the epidemic of obesity in the U.S., the occurrence of NAFLD has risen exuberantly, becoming the most common cause of liver disease. Although steatohepatitis can progress to cirrhosis and liver failure, the most common co-morbidity of NAFLD is hepatic insulin resistance and systemic abnormalities in circulating glucose, lipid, and inflammatory mediator concentrations. A complete understanding of the factors that influence the development and progression of NAFLD is needed. Recent work has suggested that the lipin family of proteins (lipin 1, 2, and 3) coordinate and connect hepatic mitochondrial and glycerolipid metabolism through their bifunctional molecular activities. Lipins are metabolic enzymes that dephosphorylate phosphatidic acid (PA) to form diacylglycerol (DAG) (PAP activity) at the endoplasmic reticulum membrane, but also act in the nucleus to regulate the expression of genes encoding mitochondrial enzymes by interacting with DNA-bound transcription factors. We have serendipitously generated a mouse model that will allow us to distinguish the two molecular functions of lipin 1 in liver. The studies proposed herein are designed to: [1] characterize and distinguish the nucleocytoplasmic effects of lipin 1 in hepatocytes, [2] to determine whether lipin 2 also has transcriptional regulatory function and define the genomic profile of its targets, and [3] to define the compensatory mechanisms facilitating hepatic triglyceride synthesis in the context of diminished PAP activity. The results f these studies will not only have implications for our understanding of the biology of lipin proteins, but will also provide new insight into the basic molecular regulation of intermediary metabolism.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phenomaster NG Mouse Metabolic Phenotyping System
  • 批准号:
    10427654
  • 项目类别:
  • 资助金额:
    $52.37万
  • 财政年份:
    2022
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10218153
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10096091
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位:
Novel insulin-sensitizing NASH/diabetes drugs.
  • 批准号:
    10471836
  • 项目类别:
  • 资助金额:
    $49.75万
  • 财政年份:
    2019
  • 负责人:
    Brian N Finck
  • 依托单位: